Actavis hit with suit over recalled Digitek

Maybe not faster than a speeding bullet, but close. Lawyers already are filing a class-action lawsuit against Iceland's Actavis over the recalled heart drug Digitek, which was just pulled off the market two weeks ago. (The suit also names Mylan, which distributed the meds.)

The generics maker pulled the drug because some batches may have included tablets that were twice the normal strength. Plaintiffs are alleging injury and asking for damages and medical monitoring in case of future health problems. At the time of the recall, Actavis said the stronger tablets might cause toxicity in renal-failure patients.

- see the item at the WSJ Health Blog

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.